{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:54:45Z","timestamp":1778633685381,"version":"3.51.4"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,8,28]],"date-time":"2017-08-28T00:00:00Z","timestamp":1503878400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s00296-017-3800-8","type":"journal-article","created":{"date-parts":[[2017,8,28]],"date-time":"2017-08-28T11:48:30Z","timestamp":1503920910000},"page":"1957-1977","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis"],"prefix":"10.1007","volume":"37","author":[{"given":"Zsombor","family":"Zrubka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanni","family":"Rencz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Z\u00e1vada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Golicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina Prevolnik","family":"Rupel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judit","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin","family":"Brodszky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Baji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guenka","family":"Petrova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandru","family":"Rotar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"Gul\u00e1csi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9636-6012","authenticated-orcid":false,"given":"M\u00e1rta","family":"P\u00e9ntek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,28]]},"reference":[{"issue":"10009","key":"3800_CR1","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/S0140-6736(15)61340-X","volume":"386","author":"Collaborators GDaH,","year":"2015","unstructured":"Collaborators GDaH, (2015) Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990\u20132013: quantifying the epidemiological transition. Lancet 386(10009):2145\u20132191","journal-title":"Lancet"},{"key":"3800_CR2","unstructured":"Eurostat (2016) Population on 1 January. \n                        http:\/\/ec.europa.eu\/eurostat\/tgm\/download.do?tab=table&plugin=1&language=en&pcode=tps00001"},{"key":"3800_CR3","unstructured":"WHO (2004) Deaths and DALY estimates for 2004 by cause for WHO Member States: Persons, all ages. \n                        http:\/\/www.who.int\/healthinfo\/global_burden_disease\/estimates_country\/en\/\n                        \n                    . Accessed 2016.09.08. 2006"},{"issue":"2","key":"3800_CR4","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00296-009-0936-1","volume":"30","author":"V Brodszky","year":"2009","unstructured":"Brodszky V, B\u00e1lint P, G\u00e9her P et al (2009) Disease burden of psoriatic arthritis compared to rheumatoid arthritis. Hungarian experiment. Rheumatol Int 30(2):199\u2013205","journal-title":"Rheumatol Int"},{"key":"3800_CR5","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00296-012-2542-x","volume":"33","author":"A Pet\u0159\u00edkov\u00e1","year":"2013","unstructured":"Pet\u0159\u00edkov\u00e1 A, Dole\u017eal T, Klime\u0161 J, Vocelka M, Sedov\u00e1 L, Kol\u00e1\u0159 J (2013) The economic burden of the ankylosing spondylitis in the Czech Republic: comparison between 2005 and 2008. Rheumatol Int 33:1813\u20131819","journal-title":"Rheumatol Int"},{"issue":"Suppl 1","key":"3800_CR6","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1007\/s10198-014-0595-3","volume":"15","author":"V Brodszky","year":"2014","unstructured":"Brodszky V, Baji P, Balogh O, P\u00e9ntek M (2014) Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ 15(Suppl 1):S65\u2013S71","journal-title":"Eur J Health Econ"},{"issue":"9539","key":"3800_CR7","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(06)69369-0","volume":"368","author":"I Boncz","year":"2006","unstructured":"Boncz I, Sebesty\u00e9n A (2006) Financial deficits in the health services of the UK and Hungary. Lancet 368(9539):917\u2013918","journal-title":"Lancet"},{"issue":"3","key":"3800_CR8","doi-asserted-by":"crossref","first-page":"e0119683","DOI":"10.1371\/journal.pone.0119683","volume":"10","author":"JT Joensuu","year":"2015","unstructured":"Joensuu JT, Huoponen S, Aaltonen KJ, Konttinen YT, Nordstrom D, Blom M (2015) The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review. PLoS ONE 10(3):e0119683","journal-title":"PLoS ONE"},{"key":"3800_CR9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2474-15-26","volume":"15","author":"MR Cawson","year":"2014","unstructured":"Cawson MR, Mitchell SA, Knight C et al (2014) Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis. BMC Musculoskelet Disord 15:26","journal-title":"BMC Musculoskelet Disord"},{"issue":"2","key":"3800_CR10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semarthrit.2014.05.001","volume":"44","author":"F Matcham","year":"2014","unstructured":"Matcham F, Scott IC, Rayner L et al (2014) The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum 44(2):123\u2013130","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"3800_CR11","first-page":"592","volume":"35","author":"MJ Harrison","year":"2008","unstructured":"Harrison MJ, Davies LM, Bansback NJ, Ingram M, Anis AH, Symmons DP (2008) The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review. J Rheumatol 35(4):592\u2013602","journal-title":"J Rheumatol"},{"issue":"3","key":"3800_CR12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"G EuroQol","year":"1990","unstructured":"EuroQol G (1990) EuroQol\u2013a new facility for the measurement of health-related quality of life. Health Policy 16(3):199\u2013208","journal-title":"Health Policy"},{"issue":"1","key":"3800_CR13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","volume":"37","author":"R Brooks","year":"1996","unstructured":"Brooks R (1996) EuroQol: the current state of play. Health Policy 37(1):53\u201372","journal-title":"Health Policy"},{"issue":"10","key":"3800_CR14","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A et al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20(10):1727\u20131736","journal-title":"Qual Life Res"},{"key":"3800_CR15","unstructured":"EuroQol G (2016) EQ-5D Homepage. \n                        http:\/\/www.euroqol.org\/home.html"},{"issue":"8","key":"3800_CR16","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hec.1608","volume":"19","author":"NJ Devlin","year":"2010","unstructured":"Devlin NJ, Parkin D, Browne J (2010) Patient-reported outcome measures in the NHS: new methods for analysing and reporting EQ-5D data. Health Econ 19(8):886\u2013905","journal-title":"Health Econ"},{"issue":"8","key":"3800_CR17","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.3899\/jrheum.110404","volume":"38","author":"MJ Harrison","year":"2011","unstructured":"Harrison MJ, Bansback NJ, Marra CA, Drummond M, Tugwell PS, Boonen A (2011) Valuing health for clinical and economic decisions: directions relevant for rheumatologists. J Rheumatol 38(8):1770\u20131775","journal-title":"J Rheumatol"},{"key":"3800_CR18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10198-014-0590-8","volume":"15","author":"L Gulacsi","year":"2014","unstructured":"Gulacsi L (2014) Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria. Eur J Health Econ 15:13\u201325","journal-title":"Eur J Health Econ"},{"issue":"11","key":"3800_CR19","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1007\/s11136-016-1375-6","volume":"25","author":"F Rencz","year":"2016","unstructured":"Rencz F, Gulacsi L, Drummond M et al (2016) EQ-5D in Central and Eastern Europe: 2000\u20132015. Qual Life Res Int J Qual Life Aspects Treatment, Care Rehabil 25(11):2693\u20132710","journal-title":"Qual Life Res Int J Qual Life Aspects Treatment, Care Rehabil"},{"key":"3800_CR20","unstructured":"WHO (2016) International Statistical Classification of Diseases and Related Health Problems 10th Revision Version: 2016. \n                        http:\/\/apps.who.int\/classifications\/icd10\/browse\/2016\/en\n                        \n                    . Accessed 14 Oct 2016"},{"key":"3800_CR21","unstructured":"Search Engine for EuroQol and EQ-5D-related material. \n                        http:\/\/www.euroqol.org\/eq-5d-publications\/search.html\n                        \n                    . Accessed 09 Jan 2016"},{"key":"3800_CR22","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535","journal-title":"BMJ"},{"key":"3800_CR23","unstructured":"Higgins JPT, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. (updated March 2011) The Cochrane Collaboration; 2011"},{"issue":"3","key":"3800_CR24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177\u2013188","journal-title":"Control Clin Trials"},{"key":"3800_CR25","unstructured":"P\u00e9ntek M, Czirjak L, Pfliegler G, et al. (2015.) Lokaliz\u00e1lt scleroderma \u00e9s sziszt\u00e9m\u00e1s sclerosis betegs\u00e9ggel \u00e9l\u0151k \u00e9letmin\u0151s\u00e9ge \u00e9s betegs\u00e9gterhe: a BURQOL-RD eur\u00f3pai felm\u00e9r\u00e9s magyarorsz\u00e1gi eredm\u00e9nyei (Quality of life and burden of disease in localised scleroderma and systemic sclerosis: Hungarian results of the European BURQOL-RD study). Immunol\u00f3giai Szemle VII. (4):21\u20139"},{"key":"3800_CR26","unstructured":"Sz\u0171cs G, G\u00e1l\u00a0J, G\u00e9her P, et al. (2015) A golimumab hat\u00e1soss\u00e1ga \u00e9s biztons\u00e1goss\u00e1ga a betegs\u00e9g lefoly\u00e1s\u00e1t m\u00f3dos\u00edt\u00f3 b\u00e1zister\u00e1pi\u00e1s szerek (DMARD-ok) mellett alkalmazva rheumatoid arthritisben: A GO-MORE vizsg\u00e1lat magyarorsz\u00e1gi eredm\u00e9nyei (Efficacy and safety of golimumab used in combination with disease modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis: Hungarian results of the GO-MORE study). Immunol\u00f3giai Szemle VII. (3):59\u201366"},{"issue":"3","key":"3800_CR27","first-page":"231","volume":"36","author":"HA Khoshab","year":"2015","unstructured":"Khoshab HA, Sloboda T (2015) Minimal access spinal technologies (MAST) fusion procedures for the treatment of the degenerative lumbar spine (a part of multicentral prospective study). Case Report. Neuro Endocrinol Lett 36(3):231\u2013235","journal-title":"Neuro Endocrinol Lett"},{"issue":"19\u201320","key":"3800_CR28","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1111\/j.1365-2702.2012.04101.x","volume":"21","author":"E Kiraly","year":"2012","unstructured":"Kiraly E, Gondos T (2012) Cardiovascular diseases and the health-related quality of life after total hip replacement. J Clin Nurs 21(19\u201320):2843\u20132850","journal-title":"J Clin Nurs"},{"issue":"2","key":"3800_CR29","first-page":"87","volume":"50","author":"Z Klemenc-Keti\u0161","year":"2011","unstructured":"Klemenc-Keti\u0161 Z (2011) Disability in patients with chronic non-specific low back pain: validation of the Slovene version of the Oswestry disability index. Slov J Publ Health 50(2):87\u201394","journal-title":"Slov J Publ Health"},{"issue":"1","key":"3800_CR30","first-page":"65","volume":"12","author":"J Pasek","year":"2012","unstructured":"Pasek J, Kwiatek P, Pasek T, Szajkowski S, Szewc A, Sieron A (2012) Application of magnetic field and visible light in the treatment of low back pain and sciatic neuralgia. Aktualnosci Neurologiczne 12(1):65\u201368","journal-title":"Aktualnosci Neurologiczne"},{"issue":"1","key":"3800_CR31","first-page":"18","volume":"9","author":"J Rosa","year":"2004","unstructured":"Rosa J, Vanuga P, Noskovic M, Ritomsky A (2004) Profile of patients presenting with postmenopausal osteoporosis treated with raloxifene. Osteol Bull 9(1):18\u201321","journal-title":"Osteol Bull"},{"key":"3800_CR32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.vhri.2014.07.001","volume":"4","author":"VP Rupel","year":"2014","unstructured":"Rupel VP, Ogorevc M (2014) Use of the EQ-5D instrument and value scale in comparing health states of patients in four health care programs among health care providers. Val Health Reg Issues 4:95\u201399","journal-title":"Val Health Reg Issues"},{"issue":"10","key":"3800_CR33","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s10067-013-2303-6","volume":"32","author":"P Horak","year":"2013","unstructured":"Horak P, Skacelova M, Hejduk K, Smrzova A, Pavelka K (2013) Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry. Clin Rheumatol 32(10):1451\u20131458","journal-title":"Clin Rheumatol"},{"issue":"4","key":"3800_CR34","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00296-010-1721-x","volume":"32","author":"A Inotai","year":"2012","unstructured":"Inotai A, Rojkovich B, Fulop A, Jaszay E, Agh T, Meszaros A (2012) Health-related quality of life and utility in patients receiving biological and non-biological treatments in rheumatoid arthritis. Rheumatol Int 32(4):963\u2013969","journal-title":"Rheumatol Int"},{"issue":"9","key":"3800_CR35","first-page":"423","volume":"144","author":"\u00c1 M\u00e9sz\u00e1ros","year":"2003","unstructured":"M\u00e9sz\u00e1ros \u00c1, Vincze Z (2003) \u00c9letmin\u0151s\u00e9g vizsg\u00e1lata asthma bronchi\u00e1l\u00e9s \u00e9s rheumatoid arthritises betegek k\u00f6r\u00e9ben. Orv Hetil 144(9):423\u2013427","journal-title":"Orv Hetil"},{"issue":"Suppl 1","key":"3800_CR36","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1007\/s10198-014-0597-1","volume":"15","author":"M Pentek","year":"2014","unstructured":"Pentek M, Gulacsi L, Rojkovich B, Brodszky V, van Exel J, Brouwer WB (2014) Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists. Eur J Health Econ 15(Suppl 1):S83\u2013S92","journal-title":"Eur J Health Econ"},{"issue":"16","key":"3800_CR37","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1556\/OH.2008.28294","volume":"149","author":"M Pentek","year":"2008","unstructured":"Pentek M, Szekanecz Z, Czirjak L et al (2008) Impact of disease progression on health status, quality of life and costs in rheumatoid arthritis in Hungary. Orv Hetil 149(16):733\u2013741","journal-title":"Orv Hetil"},{"issue":"1","key":"3800_CR38","first-page":"10","volume":"22","author":"J Z\u00e1vada","year":"2014","unstructured":"Z\u00e1vada J, Uher M, Vencovsky J, Pavelka K (2014) Assessment of utility score EQ-D and estimating the Cost-utility of the first year of treatment by TNF inhibitors in a cohort of patients with Rheumatoid Arthritis during\u2014results from the Czech biologics registry ATTRA. Ceska Revmatol 22(1):10\u201316","journal-title":"Ceska Revmatol"},{"issue":"3","key":"3800_CR39","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00198-012-2240-2","volume":"24","author":"F Borgstrom","year":"2013","unstructured":"Borgstrom F, Lekander I, Ivergard M et al (2013) The international costs and utilities related to osteoporotic fractures study (ICUROS)\u2014quality of life during the first 4\u00a0months after fracture. Osteoporos Int 24(3):811\u2013823","journal-title":"Osteoporos Int"},{"issue":"3","key":"3800_CR40","first-page":"585","volume":"21","author":"N Dimitrov","year":"2015","unstructured":"Dimitrov N, Goycheva P, Petrov D (2015) Assessment of health related quality of life in male patients with major osteoporotic fractures by two generic healt status indices: a preliminary study. J Balkan Tribol Assoc 21(3):585\u2013593","journal-title":"J Balkan Tribol Assoc"},{"issue":"4","key":"3800_CR41","first-page":"158","volume":"6","author":"M P\u00e9ntek","year":"2003","unstructured":"P\u00e9ntek M, Licker-F\u00f3ris E, Lovas K et al (2003) Az \u00e9letmin\u0151s\u00e9g\u00a0m\u00e9r\u00e9se postmenopausalis osteoporosisban szenved\u0151 betegekn\u00e9l. Ca \u00e9s Csont 6(4):158\u2013163","journal-title":"Ca \u00e9s Csont"},{"issue":"4","key":"3800_CR42","first-page":"40","volume":"3","author":"Z Voko","year":"2013","unstructured":"Voko Z, Inotai A, Horv\u00e1th C, Bors K, Speer G, Kal\u00f3 Z (2013) Csontritkul\u00e1sban szenved\u0151 betegek \u00e9letmin\u0151s\u00e9ge ([Quality of life of patients with osteoporosis in Hungary]). Lege Artis Medicinae KID 3(4):40\u201341","journal-title":"Lege Artis Medicinae KID"},{"issue":"6","key":"3800_CR43","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s10067-013-2456-3","volume":"34","author":"IK Tefner","year":"2015","unstructured":"Tefner IK, Kovacs C, Gaal R et al (2015) The effect of balneotherapy on chronic shoulder pain. A randomized, controlled, single-blind follow-up trial. A pilot study. Clin Rheumatol 34(6):1097\u20131108","journal-title":"Clin Rheumatol"},{"issue":"10","key":"3800_CR44","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1007\/s00296-011-2145-y","volume":"32","author":"IK Tefner","year":"2012","unstructured":"Tefner IK, Nemeth A, Laszlofi A, Kis T, Gyetvai G, Bender T (2012) The effect of spa therapy in chronic low back pain: a randomized controlled, single-blind, follow-up study. Rheumatol Int 32(10):3163\u20133169","journal-title":"Rheumatol Int"},{"key":"3800_CR45","doi-asserted-by":"crossref","unstructured":"Kovacs C, Bozsik A, Pecze M, et al. (2016) Effects of sulfur bath on hip osteoarthritis: a randomized, controlled, single-blind, follow-up trial: a pilot study. International journal of biometeorology","DOI":"10.1007\/s00484-016-1158-3"},{"issue":"10","key":"3800_CR46","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s10067-012-2026-0","volume":"31","author":"C Kovacs","year":"2012","unstructured":"Kovacs C, Pecze M, Tihanyi A, Kovacs L, Balogh S, Bender T (2012) The effect of sulphurous water in patients with osteoarthritis of hand. Double-blind, randomized, controlled follow-up study. Clin Rheumatol 31(10):1437\u20131442","journal-title":"Clin Rheumatol"},{"issue":"4","key":"3800_CR47","first-page":"373","volume":"50","author":"A Kulisch","year":"2014","unstructured":"Kulisch A, Benko A, Bergmann A et al (2014) Evaluation of the effect of Lake Heviz thermal mineral water in patients with osteoarthritis of the knee: a randomized, controlled, single-blind, follow-up study. Eur J Phys Rehabil Med 50(4):373\u2013381","journal-title":"Eur J Phys Rehabil Med"},{"issue":"10","key":"3800_CR48","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1007\/s00296-013-2776-2","volume":"33","author":"IK Tefner","year":"2013","unstructured":"Tefner IK, Gaal R, Koroknai A et al (2013) The effect of Neydharting mud-pack therapy on knee osteoarthritis: a randomized, controlled, double-blind follow-up pilot study. Rheumatol Int 33(10):2569\u20132576","journal-title":"Rheumatol Int"},{"issue":"6","key":"3800_CR49","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5114\/reum.2015.57634","volume":"53","author":"P Kawalec","year":"2015","unstructured":"Kawalec P, Malinowski K (2015) Disease activity, quality of life and indirect costs of reduced productivity at work, generated by Polish patients with ankylosing spondylitis. Reumatologia 53(6):301\u2013308","journal-title":"Reumatologia"},{"key":"3800_CR50","unstructured":"Mlcoch T, Sedova L, Stolfa J, et al. (2016) Mapping the relationship between clinical and quality-of-life outcomes in patients with ankylosing spondylitis. Expert Rev Pharmacoecon Outcomes Res 1\u20139"},{"issue":"4","key":"3800_CR51","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3109\/03009740903468982","volume":"39","author":"V Brodszky","year":"2010","unstructured":"Brodszky V, Pentek M, Balint PV et al (2010) Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey. Scand J Rheumatol 39(4):303\u2013309","journal-title":"Scand J Rheumatol"},{"issue":"48","key":"3800_CR52","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1556\/OH.2014.30044","volume":"155","author":"F Rencz","year":"2014","unstructured":"Rencz F, Brodszky V, Pentek M et al (2014) Disease burden of psoriasis associated with psoriatic arthritis in Hungary. Orv Hetil 155(48):1913\u20131921","journal-title":"Orv Hetil"},{"issue":"10","key":"3800_CR53","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/rheumatology\/keq165","volume":"49","author":"T Minier","year":"2010","unstructured":"Minier T, Pentek M, Brodszky V et al (2010) Cost-of-illness of patients with systemic sclerosis in a tertiary care centre. Rheumatology (Oxford) 49(10):1920\u20131928","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"3800_CR54","doi-asserted-by":"crossref","first-page":"A378","DOI":"10.1016\/j.jval.2014.08.2602","volume":"17","author":"M Jaromi","year":"2014","unstructured":"Jaromi M, Hanzel A, Endrei D et al (2014) Determination of the annual health insurance Cost Of outpatient care physiotherapy services For low back pain. Val Health J Int Soc Pharmacoecon Outcomes Res 17(7):A378","journal-title":"Val Health J Int Soc Pharmacoecon Outcomes Res"},{"issue":"Suppl 1","key":"3800_CR55","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10198-016-0786-1","volume":"17","author":"A Kuhlmann","year":"2016","unstructured":"Kuhlmann A, Schmidt T, Treskova M et al (2016) Social\/economic costs and health-related quality of life in patients with juvenile idiopathic arthritis in Europe. Eur J Health Econ 17(Suppl 1):79\u201387","journal-title":"Eur J Health Econ"},{"issue":"9","key":"3800_CR56","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2165\/11314120-000000000-00000","volume":"27","author":"S Knies","year":"2009","unstructured":"Knies S, Evers SM, Candel MJ, Severens JL, Ament AJ (2009) Utilities of the EQ-5D: transferable or not? Pharmacoeconomics 27(9):767\u2013779","journal-title":"Pharmacoeconomics"},{"key":"3800_CR57","doi-asserted-by":"crossref","unstructured":"Szende A, Oppe M, Devlin N (2007) EQ-5D value sets: inventory, comparative review and user guide. Springer","DOI":"10.1007\/1-4020-5511-0"},{"issue":"2","key":"3800_CR58","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1524-4733.2009.00596.x","volume":"13","author":"D Golicki","year":"2010","unstructured":"Golicki D, Jakubczyk M, Niewada M, Wrona W, Busschbach JJ (2010) Valuation of EQ-5D health states in Poland: first TTO-based social value set in Central and Eastern Europe. Val health J Int Soc Pharmacoecon Outcomes Res 13(2):289\u2013297","journal-title":"Val health J Int Soc Pharmacoecon Outcomes Res"},{"issue":"11","key":"3800_CR59","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35(11):1095\u20131108","journal-title":"Med Care"},{"key":"3800_CR60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10198-014-0588-2","volume":"15","author":"L Gul\u00e1csi","year":"2014","unstructured":"Gul\u00e1csi L (2014) Biological and biosimilar therapies in inflammatory conditions: challenges for the Central and Eastern European countries. Eur J Health Econ 15:1\u20134","journal-title":"Eur J Health Econ"},{"issue":"4","key":"3800_CR61","first-page":"662","volume":"35","author":"A Boonen","year":"2008","unstructured":"Boonen A, Patel V, Traina S, Chiou CF, Maetzel A, Tsuji W (2008) Rapid and sustained improvement in health-related quality of life and utility for 72\u00a0weeks in patients with ankylosing spondylitis receiving etanercept. J Rheumatol 35(4):662\u2013667","journal-title":"J Rheumatol"},{"issue":"5","key":"3800_CR62","doi-asserted-by":"crossref","first-page":"852","DOI":"10.3346\/jkms.2008.23.5.852","volume":"23","author":"C-B Choi","year":"2008","unstructured":"Choi C-B, Kim T-J, Park H-J et al (2008) Safety and clinical responses in Ankylosing Spondylitis after three months of etanercept therapy. J Korean Med Sci 23(5):852\u2013856","journal-title":"J Korean Med Sci"},{"key":"3800_CR63","first-page":"167","volume":"6","author":"AH M\u00f8ller","year":"2015","unstructured":"M\u00f8ller AH, Erntoft S, Vinding GR, Jemec GBE (2015) A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values. Patient Related Outcome Meas 6:167\u2013177","journal-title":"Patient Related Outcome Meas"},{"issue":"7","key":"3800_CR64","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/jdv.12884","volume":"29","author":"F Rencz","year":"2015","unstructured":"Rencz F, Hollo P, Karpati S et al (2015) Moderate to severe psoriasis patients\u2019 subjective future expectations regarding health-related quality of life and longevity. J Eur Acad Dermatol Venereol 29(7):1398\u20131405","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"3800_CR65","first-page":"941","volume":"30","author":"AS Russell","year":"2003","unstructured":"Russell AS, Conner-Spady B, Mintz A, Mallon C, Maksymowych WP (2003) The responsiveness of generic health status measures as assessed in patients with rheumatoid arthritis receiving infliximab. J Rheumatol 30(5):941\u2013947","journal-title":"J Rheumatol"},{"issue":"6","key":"3800_CR66","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3899\/jrheum.130864","volume":"41","author":"CO Bingham 3rd","year":"2014","unstructured":"Bingham CO 3rd, Weinblatt M, Han C et al (2014) The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial. J Rheumatol 41(6):1067\u20131076","journal-title":"J Rheumatol"},{"issue":"1","key":"3800_CR67","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/rheumatology\/keq325","volume":"50","author":"W Kievit","year":"2011","unstructured":"Kievit W, Fransen J, Adang EM et al (2011) Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford) 50(1):196\u2013203","journal-title":"Rheumatology (Oxford)"},{"key":"3800_CR68","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13075-016-0950-0","volume":"18","author":"A Gulfe","year":"2016","unstructured":"Gulfe A, Wallman JK, Kristensen LE (2016) EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden. Arthritis Res Ther 18:51","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"3800_CR69","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/acr.21619","volume":"64","author":"L Buitinga","year":"2012","unstructured":"Buitinga L, Braakman-Jansen LM, Taal E et al (2012) Comparative responsiveness of the EuroQol-5D and Short Form 6D to improvement in patients with rheumatoid arthritis treated with tumor necrosis factor blockers: results of the Dutch Rheumatoid Arthritis Monitoring registry. Arthritis Care Res (Hoboken) 64(6):826\u2013832","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"3800_CR70","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/rheumatology\/36.5.551","volume":"36","author":"NP Hurst","year":"1997","unstructured":"Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A (1997) Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 36(5):551\u2013559","journal-title":"Br J Rheumatol"},{"issue":"Suppl 1","key":"3800_CR71","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1007\/s10198-014-0596-2","volume":"15","author":"M Pentek","year":"2014","unstructured":"Pentek M, Rojkovich B, Czirjak L et al (2014) Acceptability of less than perfect health states in rheumatoid arthritis: the patients\u2019 perspective. Eur J Health Econ 15(Suppl 1):S73\u2013S82","journal-title":"Eur J Health Econ"},{"issue":"11","key":"3800_CR72","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2165\/00019053-200826110-00005","volume":"26","author":"HS Ruchlin","year":"2008","unstructured":"Ruchlin HS, Insinga RP (2008) A review of health-utility data for osteoarthritis: implications for clinical trial-based evaluation. Pharmacoeconomics 26(11):925\u2013935","journal-title":"Pharmacoeconomics"},{"key":"3800_CR73","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/S1297-319X(10)70004-X","volume":"77","author":"A Leboime","year":"2010","unstructured":"Leboime A, Confavreux CB, Mehsen N, Paccou J, David C, Roux C (2010) Osteoporosis and mortality. Joint Bone Spine 77:S107\u2013S112","journal-title":"Joint Bone Spine"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-017-3800-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-017-3800-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-017-3800-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T07:34:05Z","timestamp":1509953645000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-017-3800-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,28]]},"references-count":73,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3800"],"URL":"https:\/\/doi.org\/10.1007\/s00296-017-3800-8","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,28]]}}}